December 11th, 2pm – 3:30 PM CET

Logo_tagline_RGB_72
white-photo

This webinar updated EFPIA members on Medicines Adaptive Pathways to Patients (MAPPs) and its potential impact on research, development, licensing, HTA, and pricing & reimbursement in relation to early patient access mechanisms.

Featuring: (in order of appearance)

Jeremy-Haigh
Jeremy Haigh,
European Chief Operating Officer, Research & Development
Amgen Ltd.		 James Anderson,
Director of EU Industry & External Partnerships,
GSK
Karin Van Baelen,
‎Head Global Regulatory Affairs
Janssen, Pharmaceutical Companies of Johnson and Johnson		 Magda Chlebus,
‎Director Science Policy
EFPIA

white-photo

The topics of discussion are:

  • Medicines Adaptive Pathways to Patients,  their benefits for companies, patients, regulators and payers
  • Opportunities and barriers to implementing MAPPs
  • The status of activities which implement or support implementation of MAPPs (EMA, HTA bodies, Innovative Medicines Initiatives, Newdigs, etc)

 

Programme: 90 Minutes
What are MAPPs? Jeremy Haigh
Initiatives supporting adaptive licensing and access James Anderson
Overview of EMA Pilot and NewDigs
Karin Van Baelen
Overview of the US initiative Breakthrough Designation
Collaborative initiatives to progress and enable MAPPs implementation Magda Chlebus
Overview of IMI2 activities and plans
Q&A until End

white-photo